TD Cowen lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $5 from $10 and keeps a Buy rating on the shares. The firm says management should not have given the overly optimistic year 2 guidance at the beginning of the launch. Still, this quarter-over-quarter performance is disappointing on nearly all fronts, with dynamics not highlighted earlier this year. The slashing of guidance was not nice to see but necessary, TD Cowen says, adding that it is holding on hope that this team can get back on track.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics price target lowered to $25 from $30 at Chardan
- Iovance price target lowered to $20 from $32 at H.C. Wainwright
- Iovance downgraded to Market Perform from Outperform at Citizens JMP
- Iovance Biotherapeutics Reports Q1 2025 Financial Results
- Iovance Biotherapeutics: Buy Rating Amid Signs of Recovery and Growth Potential
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue